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Abstract
Introduction: Longevity is commonly associated with good health and with delayed onset of age-related diseases with usually benign 
course. Leptin (LEP) significantly affects metabolism and numerous functions of the organism. To find out if extreme longevity and its 
phenotype are associated with genetic variants of leptin and leptin receptor (LEPR) genes, we analysed the frequencies of the –2548 G/A 
and +19 G/A LEP, as well as the K109R, Q223R, and K656N LEPR polymorphisms in centenarians and in control groups. 
Material and methods: The frequencies of the LEP and LEPR polymorphisms were tested by restriction fragment length polymorphism 
in 128 centenarians, 414 young controls (Y), 226 myocardial infarction (MI) patients, and 190 type 2 diabetes mellitus (DM2) patients. 
Results: The GG genotype of the –2548 G/A LEP polymorphism was significantly more common in centenarians than in the Y, MI and DM2 
groups (p = 0.048, p = 0.003, p = 0.049, respectively). In addition, the AA genotype of the K109R LEPR polymorphism was significantly 
less frequent in centenarians than in the Y, MI, and DM2 groups (p = 0.026, p = 0.013, and p = 0.001, respectively). 
Conclusions: We suggest that the leptin pathway plays a role in the regulation of longevity, possibly by modulating the risk of develo-
pment of MI and of DM2. (Endokrynol Pol 2014; 65 (1): 11–16)
Key words: leptin gene (LEP); leptin receptor gene (LEPR); polymorphism; longevity; centenarians; myocardial infarction (MI);  
type 2 diabetes mellitus (DM2)
Streszczenie
Wstęp: Długowieczności często towarzyszy dobry stan zdrowia, opóźnione zachorowanie na „choroby związane z wiekiem”, których 
przebieg jest zwykle łagodny. Leptyna (LEP) znacząco wpływa na metabolizm oraz na inne funkcje organizmu. Aby sprawdzić, czy 
ekstremalna długowieczność i jej fenotyp są powiązane z odmianami genów leptyny i receptora leptyny (LEPR), przebadaliśmy częstość 
występowania polimorfizmów –2548 G/A i +19 G/A genu LEP oraz K109R, Q223R, i K656N genu LEPR u stulatków i w grupach kontrolnych. 
Materiał i metody: Częstość występowania polimorfizmów genów LEP i LEPR badano metodą analizy długości fragmentów restrykcyjnych 
u 128 stulatków, 414 młodych kontroli (Y), 226 pacjentów z zawałem serca (MI) i u 190 pacjentów z cukrzycą 2 typu (DM2). 
Wyniki: Genotyp GG polimorfizmu –2548 G/A genu LEP był znamiennie częstszy u stulatków niż w grupach Y, MI i DM2 (odpowiednio 
p = 0,048, p = 0,003 i p = 0,049). Genotyp AA polimorfizmu K109R genu LEPR był znamiennie rzadszy u stulatków niż w grupach Y, MI 
i DM2 (odpowiednio p = 0,026, p = 0,013 i p = 0,001). 
Wnioski: Sugerujemy, że szlak oddziaływań leptyny bierze udział w regulowaniu długości życia, być może poprzez modulowanie ryzyka 
zachorowania na MI i DM2. (Endokrynol Pol 2014; 65 (1): 11–16)
Słowa kluczowe: gen leptyny (LEP); gen receptora leptyny (LEPR); polimorfizm; długowieczność; stulatkowie; zawał serca (MI);  
cukrzyca 2 typu (DM2) 
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Introduction
Leptin (LEP) is a protein hormone with structural 
similarities to long-chain helical cytokines. It is secreted 
mainly by adipose tissue and, in small amounts, by 
other tissues [1]. LEP regulates appetite and energy bal-
ance and is associated with body mass and composition, 
and with BMI [2]. It also co-regulates other functions 
of the organism [3–11]. LEP acts on target tissues via 
ubiquitously expressed, membrane-localised receptors 
(LEPR) that display a structural similarity with the class 
I cytokine receptor family [12]. 
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The majority of published data indicate that ageing 
is associated with an increase in the LEP serum level [13, 
14], although some reports suggest the opposite correla-
tion [15]. Age-related hyperleptinemia correlates with 
resistance to LEP function on fat distribution and on 
insulin action [8, 16]. Hyperleptinemia and LEP resist-
ance in elderly humans are risk factors for calcification of 
vascular cells [17], aggregation of platelets [18], increased 
oxidation of LDL particles [19], hypertension [20], obesity 
[21], impaired insulin signalling [22], coronary artery 
disease and metabolic syndrome [23], as well as stroke 
[24, 25], low bone density [6, 26], cancer [27] etc. 
This prompted us to hypothesise that certain LEP 
and LEPR functional polymorphisms might extend life 
by lowering the risk of developing age-related diseases 
such as diabetes, cardiovascular disease and cancer, 
as well as by influencing the ageing process through 
modulation of metabolism and of insulin function. 
To verify our hypothesis, we analysed the frequen-
cies of the –2548 G/A, and +19 G/A LEP, as well as 
the K109R A/G, Q223R A/G, and K656N G/C LEPR 
polymorphisms in centenarians, in young persons, 
in myocardial infarction (MI) patients, and in type 2 
diabetes (DM2) patients. The polymorphisms were 
selected on the basis of their proven functionality or 
association with the risk of development of diseases 
the frequency of which is increased in aged humans 
(see ‘Discussion’ for details). 
We here present evidence that the frequency of 
certain LEP and LEPR polymorphisms is significantly 
different in centenarians and in young controls, in MI, 
and in DM2 patients, suggesting that the LEP axis may 
play a role in the regulation of longevity.
Material and methods
Study participants
A cross-sectional analysis of the LEP and LEPR genetic 
variants was performed in: 128 Polish centenarians never 
diagnosed with myocardial infarction (MI) or with type 
2 diabetes mellitus (DM2) (C, 99.58-107.25 years, mean ± 
SD 101.11 ± 1.19 years, 112 females and 16 males) — par-
ticipants in the ‘PolStu2001’ study [28]; in a young control 
group consisting of 414 blood donors and volunteers (Y, 
18–45 years, mean 27.1 ± 7.3 years, 233 females and 181 
males) with no signs and symptoms of any disease; in 
a myocardial infarction (MI) control group consisting 
of 226 patients, (first MI at the age of 28–55 years, mean 
46.9 ± 5.3 years, 59 females, 167 males); and in a type 2 
diabetes mellitus (DM2) control group consisting of 190 
patients (diagnosed at the age of 26–55, mean 47.2 ± 5.3 
years, 120 females, 70 males). Some of the MI and DM2 
patients were participants of the ‘PolSenior’ study of the 
ageing population in Poland [29].
All participants gave written informed consent 
for participation in the study. The study protocol was 
approved by the Bioethical Committee of the Medical 
University of Warsaw. 
DNA isolation and analysis of restriction  
fragment length polymorphisms 
Four ml blood samples were used for the isolation 
of the genomic DNA; this was performed using the 
salting-out procedure [30]. Genotyping of the selected 
polymorphisms in LEP and in LEPR was done by PCR 
amplification followed by digestion with an appropri-
ate restriction enzyme (restriction fragment length 
polymorphism method — RFLP). PCR-RFLP conditions 
used for the analysis are shown in Table I. The Q223R 
polymorphism of LEPR was analysed as previously de-
scribed [31]. Conditions for the analysis of the remain-
ing polymorphisms were developed in our laboratory. 
The restriction fragments obtained were visualised on 
2–3% agarose gels.
Statistical analysis
All analyses were performed using the Statistica soft-
ware package (StatSoft, Tulsa, OK, USA). Hardy-Wein-
berg equilibrium and differences in genotype frequen-
cies in the introductory analysis, as well as between the 
analysed age/disease groups, were checked with the 
chi2 test. The distribution of genotypes was analysed in 
three models of inheritance: dominant, recessive and 
codominant using 2 × 2, 2 × 2, 3 × 2 contingency tables, 
respectively. The differences in quantitative parameters 
between genotypes in the C group were assessed using 
ad-hoc test (Kruskal-Wallis ANOVA for cholesterol or 
ANOVA for other parameters) and post-hoc tests (Stu-
dent’s t-test for cholesterol or U Mann-Whitney test for 
other parameters). For all tests, the level of significance 
was established at 0.05. 
Results
Distribution of the LEP and LEPR polymor-
phisms in centenarians vs. young individuals
Two polymorphisms in the leptin gene promoter (–2548 
G/A, +19 G/A) and three amino acid sequence-changing 
polymorphisms in the leptin receptor-encoding gene 
(K109R A/G, Q223R A/G, K656N G/C) were studied. 
The frequencies of each genotype in centenarians and 
in young controls are shown in Table II.
Introductory analysis was performed in Y subjects. 
No significant sex-dependent differences in the frequen-
cies of these polymorphisms were detected. Similarly, 
combined analysis of Y subjects and of C subjects showed 
that the distribution of the analysed polymorphisms did 
not differ significantly between sexes. 
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Next, the LEP and LEPR polymorphisms were 
compared in the two age groups. We found that the 
GG genotype of the –2548 G/A LEP polymorphism 
was significantly more frequent in centenarians than in 
young controls (43.75% v. 33.57%, p = 0.048, OR = 1.539 
[95% CI: 1.006–2.352]). The +19 G/A LEP polymorphism 
was similarly distributed.
The K109R LEPR polymorphism was also differently 
distributed among the two groups: the AA genotype 
was significantly less frequent in the C group than in 
the Y group (41.40% v. 52.66%, p = 0.026, OR = 0.635 
[95% CI: 0.417–0.967]). For the Q223R and K656N LEPR 
polymorphisms, no significant differences in the distri-
bution of genotypes were observed between the groups. 
Distribution of the LEP and LEPR  
polymorphisms in centenarians vs.  
myocardial infarction patients
The frequencies of the same polymorphisms in myo-
cardial infarction patients (MI) are shown in Table II. 
We found no significant differences in the distribution 
of all analysed LEP polymorphisms between the MI 
Table I. PCR-RFLP conditions used for the analysis of the selected polymorphisms in the LEP and in the LEPR genes
Tabela I. Warunki PCR-RFLP użyte do analizy wybranych polimorfizmów genów LEP i LEPR
Gene Polymorphism Primers Tm (
oC) PCR product  
(bp)
Restriction 
enzyme
Alleles  
(bp)
LEP –2548 G/A F: 5’TGGGTACTTATACAACAAGAATAAACA3’ 54 325 HhaI A: 325
R: 5’AAAGCAAAGACAGGCATAAAAA3’ G: 180, 145
+19 G/A F: 5’ATGGAGCCCCGTAGGAATC3’ 59 220 TaaI G: 220
R: 5’CAGCTCCCGGTAACCTTCTA3’ A: 188, 32
LEPR K109R A/G F: 5’CTTTTGCCTGCTGGACTCTC3’ 59 217 BsuRI A: 217
R: 5’AAACTAAAGAAT 
TTACTGTTGAAACAAATGGC3’
G: 186, 31
Q223R A/G F: 5’ACCCTTTAAGCTGGGTGTCCCAAATAG3’ 56 416 BseNI A: 221, 125, 71
R: 5’AGCTAGCAAATATTTTTGTAAGCAATT3’ G: 186, 31
K656N G/C F: 5’ACTAGATGGACTGGGATATTGGAGTAAT3’ 56 251 BstUI G: 251
R: 5’CTTCCAAAGTAAAGTGACATTTTTCGC3’ C: 231, 20
Tm — melting temperature; F — forward; R — reverse; bp — base pairs
Table II. Frequencies of the examined genotypes in centenarians, young study subjects, myocardial infarction (MI), and type 2 
diabetes mellitus (DM2) patients (%)
Tabela II. Częstość badanych genotypów u stulatków, młodych kontroli, pacjentów z zawałem serca (MI), pacjentów z cukrzycą 
typu 2 (DM2) (%) 
LEP 
–2548 G/A
LEP 
+19 G/A
LEPR 
K109R A/G
LEPR 
Q223R A/G
LEPR 
K656N G/C
Centenarians
(n = 128)
GG
GA
AA
43.75
42.19
14.06
GG
GA
AA
32.00
42.40
25.60
AA
AG
GG
41.40
50.00
 8.60
AA
AG
GG
24.22
46.87
28.91
GG
GC
CC
78.91
17.97
 3.12
Young controls
(n = 414)
GG
GA
AA
33.57
49.03
17.40
GG
GA
AA
33.65
48.56
17.79
AA
AG
GG
52.66
41.30
 6.04
AA
AG
GG
28.02
49.76
22.22
GG
GC
CC
71.74
26.57 
 1.69
MI 
(n = 226)
GG
GA
AA
29.64
53.10
17.26
GG
GA
AA
31.41
53.10
15.49
AA
AG
GG
52.11
38.16
 9.73
AA
AG
GG
26.11
47.78
26.11
GG
GC
CC
72.57
25.22
 2.21
DM2 
(n = 190)
GG
GA
AA
37.37
51.05
11.58
GG
GA
AA
29.47
50.00
20.53
AA
AG
GG
58.42
33.68
 7.90
AA
AG
GG
25.26
51.58
23.16
GG
GC
CC
75.79
20.53
 3.68
14
PR
A
C
E 
O
RY
G
IN
A
LN
E
Leptin and leptin receptor genes and longevity  Małgorzata Roszkowska-Gancarz et al.
and Y groups. However, comparison of the C and MI 
groups revealed that polymorphisms of the LEP gene 
promoter were differentially distributed: the GG geno-
type of the –2548 G/A polymorphism was more frequent 
in centenarians than in MI patients (43.75% v. 29.64%, 
p = 0.003, OR = 1.85 [95% CI: 1.18–2.89]).
No significant differences in frequencies of the 
K109R, Q223R and K656N LEPR polymorphisms 
were detected between the MI and Y groups. The AA 
genotype of the K109R was significantly less frequent 
in the C group than in the MI group (41.40% v. 52.11%, 
p = 0.013, OR = 0.65 [95% CI: 0.42–1.00]). The differ-
ences in distribution of the remaining two LEPR poly-
morphisms in the C vs. MI groups were insignificant. 
Distribution of the LEP and LEPR  
polymorphisms in centenarians v. type 2  
diabetes mellitus patients
Analysis of the frequencies of the polymorphisms under 
study in type 2 diabetes mellitus patients (Table II) gave 
the following results. 
The AA genotype of the –2548 G/A LEP polymor-
phism was significantly less frequent in the DM2 group 
than in the Y group (11.58% v. 17.40%, p = 0.018, OR 
= 1.60 [95% CI: 0.96–2.67]). The genotypes of the +19 
G/A LEP polymorphism were not differently distributed 
among these groups. Comparison of the C and DM2 
groups showed that the GG genotype of the –2548 G/A 
LEP polymorphism was significantly more common in 
centenarians (43.75% v. 37.37%, p = 0.049, OR = 1.3 
[95% CI: 0.83–2.05]). The +19 G/A polymorphism was 
distributed equally in the C and DM2 groups.
Analysis of the LEPR polymorphisms indicated 
that the AA genotype of the K109R polymorphism and 
the GG genotype of the K656N polymorphism were 
less frequent in the Y group than in the DM2 group 
(K109R: 52.66% v. 58.42%, p = 0.029, OR = 0.79 [95% 
CI: 0.561.12]; K656N: 71.74% v. 75.79%, p = 0.046, OR 
= 0.81 [95% CI: 0.54–1.20]), while the frequencies of the 
Q223R genotypes did not differ between these groups. 
The AA genotype of the K109R polymorphism was also 
significantly less frequent in the C group than in the 
DM2 group (41.40% v. 58.42%, p = 0.001, OR = 0.50 
[95% CI: 0.32–0.79], respectively). The frequencies of 
the remaining LEPR genotypes did not differ between 
these groups.
Correlations of the LEP and LEPR polymorphisms 
with metabolic variables in centenarians
The metabolic variables of the C group were as follows: 
body mass index (BMI) 15.3–37.4 kg/m2, mean ± SD 
23.6 ± 4.4 kg/m2; fasting glucose 26–315 mg/dL, mean ± SD 
86.7 ± 31.8 mg/dL; insulin 5.82-586 pmol/L, mean ± SD 
58.73 ± 81.18 pmol/L; total cholesterol 100–316 mg/dL, 
mean ± SD 195.3 ± 45.4 mg/dL; HDL cholesterol 26– 
–136 mg/dL, mean ± SD 60.0 ± 17.7 mg/dL; triglycerides 
45–436 mg/dL, mean ± SD 108.8 ± 51.4 mg/dL. As-
sociation analysis of genotypes of the LEP and LEPR 
polymorphisms with these metabolic measures was 
performed. 
The Q223R LEPR polymorphism correlated with 
fasting glucose: carriers of the AA genotype of this 
polymorphism had a significantly lower mean fasting 
glucose level than GG homozygotes (80.12 ± 12.21 mg/dL 
v. 95.75 ± 39.42 mg/dL, p = 0.002). They also had a sig-
nificantly lower mean fasting insulin level than carriers 
of at least one G allele (44.59 ± 78.92 pmol/L v. 64.52 ± 
± 87.53 pmol/L, p = 0.013), and GG homozygotes (44.59 ± 
± 78.92 pmol/L v. 52.74 ± 46.91 pmol/L, p = 0.06).
We found no significant associations between the 
G-2548A and G+19A LEP, as well as the K109R and 
K656N LEPR genotypes and BMI, fasting glucose, total 
cholesterol, HDL cholesterol, and triglycerides levels.
Discussion and conclusions
Ageing is accompanied by an increased risk of develop-
ing cardiovascular disease, cancer, diabetes, osteoporo-
sis, sarcopenia and diseases related to immune system 
dysfunction. All these conditions negatively affect 
longevity. It is well documented that age progression is 
associated with an increase in the level of LEP [13, 14]; 
however, this rule does not seem to apply to centenar-
ians [32]. To ascertain whether LEP signalling has an 
impact on extreme longevity, which is usually associ-
ated with good health and delayed occurrence of typical 
age-related diseases, we analysed the frequencies of the 
–2548 G/A and +19 G/A LEP, as well as the K109R A/G, 
Q223R A/G, and K656N G/C LEPR polymorphisms in 
centenarians and compared them to their frequencies 
in young individuals, as well as in MI and in DM2 
patients who were diagnosed before the age of 55. We 
purposely selected young MI and DM2 patients, since 
a genetic predisposition towards development of various 
diseases plays a more important role in young than in 
old persons and, therefore, can be more easily detected. 
We found that the GG genotype of the –2548 G/A 
LEP promoter polymorphism is significantly more 
common in centenarians never diagnosed with MI 
or with DM2 than in young controls, and in the MI 
and DM2 groups. This finding seems to contrast with 
previously published data showing that the G allele of 
this polymorphism is associated with obesity [33, 34]. 
There are at least three potential explanations for such 
a discrepancy: first, obesity at a younger age might be 
of low importance for extreme longevity; second, this 
polymorphism might be a low-importance regulatory 
factor of longevity; third, a protective role of this geno-
15
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type against development of MI or DM2 might prevail 
over its influence on obesity. This third hypothesis 
seems to be the most probable, since, as mentioned 
above, we also found that this genotype was signifi-
cantly more common in the C group than in the MI and 
DM2 groups. In addition, overrepresentation of this 
genotype in the C group remains in agreement with 
previous findings that it is the A allele which increases 
the risk of development of non-small cell lung cancer, 
oral, prostate and breast cancers, as well as non-Hodg-
kin’s lymphoma [35–41]. Indeed, our centenarian study 
subjects rarely suffered from neoplastic disease: only 
two of them had cancers (uterus or thyroid), and six 
others had non-melanoma-type skin cancer of benign 
clinical course in sun-exposed skin areas. 
The +19 G/A LEP promoter polymorphism, had not 
been extensively studied; however, available reports 
show that its GG and GA genotypes correlate with the 
risk of various cancers [35, 42, 43]. We found that it was 
related neither to longevity, nor to MI or DM2.
The K109R LEPR polymorphism is the next one that 
is associated with extreme longevity. We showed that 
its AA genotype is significantly less common in the C 
group than in the Y, MI and DM2 groups. This remains 
in agreement with previous findings that this genotype 
is associated with obesity [44] and with increased DM2 
risk [45]. 
The presence of the Q223R LEPR G allele was pre-
viously associated with obesity [46–48]. However, the 
findings regarding its association with altered glucose 
and lipid metabolism are conflicting [48–51]. In addi-
tion, the GG genotype of this polymorphism correlates 
with increased risk of breast carcinoma and of oral 
cancer [38, 39, 41]. We showed in this work that this 
polymorphism is in fact not associated with longevity. 
Inconsistency of the available data regarding its role in 
morbidity makes plausible the idea that this polymor-
phism does not play a role in longevity regulation. Be 
that as it may, we should remember that the C group 
might not be sufficiently large to show a correlation. 
While correlating metabolic parameters’ values 
with the LEP and LEPR genotypes, we found that 
centenarian carriers of the Q223R LEPR AA genotype 
paradoxically had a significantly lower mean fasting 
glucose and insulin levels compared to carriers of 
other genotypes. 
This finding is of great importance since it has been 
previously found that low-normal fasting glucose lev-
els are associated with lower risk of DM2 compared 
to high-normal values [52, 54]. Our results remain in 
agreement with those of Chin et al. and of Takahashi-
Yasuno et al. [49, 50]. 
This study presents only preliminary data and has 
several limitations. First, the LEP and LEPR polymor-
phism frequencies were analysed only in young and in 
centenarian age groups, while it would have been more 
informative to test an additional group of intermedi-
ate age. Second, the number of centenarians, although 
high if compared to centenarian groups analysed in 
the majority of other publications, amounted to only 
128; therefore, our results should be confirmed on 
a much larger group of centenarians of various ethnic 
backgrounds. Third, it could be objected that our study 
groups were uneven with respect to sex distribution. 
This is, however, of little or no significance since our 
introductory analysis showed no association of the 
analysed polymorphisms with sex. 
To sum up, we suggest that the leptin pathway could 
impact upon human longevity. We also suggest that this 
might be so, at least in part, because of the modulation 
of the risk of developing cardiovascular disease and 
type 2 diabetes mellitus.
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